(Q38983259)

English

Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

rheumatoid arthritis

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Yara Hahr Marques Hökerberg

5

object named as

Yara Hahr Marques Hökerberg

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Vanderlea Poeys Cabral

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Carlos Augusto Ferreira de Andrade

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sonia Regina Lambert Passos

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Maria de Fátima Moreira Martins

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

1 October 2016

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Revista Brasileira de reumatologia

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Pharmacovigilance in perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.RBR.2016.07.008

21 January 2018

Identifiers

10.1016/J.RBR.2016.07.008

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38983259&oldid=2202419000"